ChipDX was an online data analysis platform I developed in 2010 to analyse genomic data from cancer patients and generate accurate, clinically-useful results.
After uploading a patient’s raw data file, the user could select from one or more analysis modules, including data quality control, prediction of tumour recurrence/survival, treatment response or identification of a metastatic tumour’s primary tissue of origin.
The system can be accessed for research-use-only at www.chipdx.com and is now owned by Signal Genetics, where it is used to manage the analysis and reporting of a proprietary genetic test for patients diagnosed with multiple myeloma; MyPRS.
- Design and multiseries validation of a web-based gene expression assay for predicting breast cancer recurrence and patient survival
RK Van Laar, The Journal of Molecular Diagnostics 13 (3), 297-304
- An online gene expression assay for determining adjuvant therapy eligibility in patients with stage 2 or 3 colon cancer
RK Van Laar, British journal of cancer 103 (12), 1852
- Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer
RK Van Laar, BMC medical genomics 5 (1), 30